Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Delavirdine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.63 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.63 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.63 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.63 |
| ▸ | MAOA | P21397 | 1/20 | 0.63 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.63 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.63 |
| ▸ | MDH1 | P40925 | 1/20 | 0.63 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.63 |
| ▸ | CYP46A1 | Q9Y6A2 | 7/20 | 0.45 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.45 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.45 |
| ▸ | PGR | P06401 | 1/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.45 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Delavirdine SCHEMBL6939091 | 0.91 | ADORA3 (0.52) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL29714124 | 0.80 | ADRA2A (1.00) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL29602259 | 0.80 | ADRA2A (1.00) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL34420 | 0.80 | ADRA2A (1.00) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL30803764 | 0.80 | ADRA2A (1.00) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL3221265 | 0.79 | ADRA2A (0.98) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL28170537 | 0.79 | ADRA2A (0.98) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL40522 | 0.79 | ADRA2A (0.98) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL29585604 | 0.79 | ADRA2A (0.98) | ADORA3ABCG2ADRA2ACHRM1MAOA | |
| Delavirdine SCHEMBL29746247 | 0.78 | ADRA2A (0.97) | ADORA3ABCG2ADRA2ACHRM1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 108 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240218377-A1 | BISPECIFIC APTAMER FOR TREATING CANCER | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2024-07-04 | — | — | US | disclosed |
| CN-114727999-A | Capsid inhibitors for the prevention of HIV | 吉利德科学公司 | 2022-07-08 | — | — | CN | disclosed |
| US-11332747-B2 | Bispecific aptamer for treating cancer | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3908314-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | Memorial Sloan Kettering Cancer Center (US) | 2021-11-17 | — | — | EP | disclosed |
| US-11110150-B2 | Complexes of IL-15 and IL-15Ralpha and uses thereof | NOVARTIS AG (CH) | 2021-09-07 | — | — | US | disclosed |
| US-20210162076-A1 | Aptamer Compositions and Methods of Use Thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2021-06-03 | — | — | US | disclosed |
| US-10960086-B2 | Aptamer compositions and methods of use thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2021-03-30 | — | — | US | disclosed |
| WO-2020146835-A1 | MULTIMERIZATION OF IL-15/IL-15R-ALPHA-FC COMPLEXES TO ENHANCE IMMUNOTHERAPY | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-16 | — | — | WO | disclosed |
| US-10689654-B2 | Bivalent siRNA chimeras and methods of use thereof | AUGUSTA UNIVERSITY RESEARCH INSTITUTE, INC. (US) | 2020-06-23 | — | — | US | disclosed |
| US-20200157542-A1 | Bispecific Aptamer for Treating Cancer | UNITED STATES GOVERNMENT | 2020-05-21 | — | — | US | disclosed |
| WO-2010014913-A1 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE | VENTIRX PHARMACEUTICALS, INC. (US) | 2010-02-04 | — | — | WO | disclosed |
| US-20100029585-A1 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE | VENTIRX PHARMACEUTICALS, INC. | 2010-02-04 | — | — | US | disclosed |
| WO-2009136979-A2 | COMPOUNDS THAT MODULATE NEGATIVE-SENSE, SINGLE-STRANDED RNA VIRUS REPLICATION AND USES THEREOF | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-11-12 | — | — | WO | disclosed |
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | KADMON CORPORATION, LLC | 2009-09-24 | — | — | US | disclosed |
| WO-2009023059-A2 | TREATMENT OF VIRAL INFECTIONS BY MODULATION OF HOST CELL METABOLIC PATHWAYS | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2009-02-19 | — | — | WO | disclosed |
| WO-2009008924-A2 | METHODS OF PREVENTING AND TREATING VIRAL INFECTIONS BY INHIBITING THE DEISGYLATION ACTIVITY OF OTU DOMAIN-CONTAINING VIRAL PROTEINS | MOUNT SINAI SCHOOL OF MEDICINE OF NEW YORK UNIVERSITY (US) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008127274-A2 | HETEROCYCLIC INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2008127275-A2 | PYRROLINONE COMPOUNDS AS INHIBITORS OF BACTERIAL PEPTIDYL TRNA HYDROLASE AND USES THEREOF | PTC THERAPEUTICS, INC. (US) | 2008-10-23 | — | — | WO | disclosed |
| WO-2006118916-A2 | METHODS AND COMPOSITIONS FOR POLYTOPIC VACCINATION | POLYTOPOS, LLC (US) | 2006-11-09 | — | — | WO | disclosed |
| US-20060246081-A1 | Methods and compositions for polytopic vaccination | POLYTOPOS, LLC | 2006-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090239830-A1 | Treatment of viral infections by modulation of host cell metabolic pathways | GOT2, MAVS, ME3 | ADORA3 1757/4885ABCG2 958/4885ADRA2A 4112/4885 |
| US-20100029585-A1 | TOLL-LIKE RECEPTOR AGONIST FORMULATIONS AND THEIR USE | TLR8, TLR7, TLR1 | ADORA3 442/4885ABCG2 890/4885ADRA2A 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.